血清镁水平升高促使接受免疫检查点阻断剂治疗的癌症患者获得良好疗效

IF 7.6 1区医学 Q1 ONCOLOGY

European Journal of Cancer Pub Date : 2024-10-11 DOI:10.1016/j.ejca.2024.115069

Yingfang Feng , Meng Gao , Xiyue Xu , Hengqi Liu , Ke Lu , Zheng Song , Jingwei Yu , Xia Liu , Xue Han , Lanfang Li , Lihua Qiu , Zhengzi Qian , Shiyong Zhou , Huilai Zhang , Xianhuo Wang

{"title":"血清镁水平升高促使接受免疫检查点阻断剂治疗的癌症患者获得良好疗效","authors":"Yingfang Feng , Meng Gao , Xiyue Xu , Hengqi Liu , Ke Lu , Zheng Song , Jingwei Yu , Xia Liu , Xue Han , Lanfang Li , Lihua Qiu , Zhengzi Qian , Shiyong Zhou , Huilai Zhang , Xianhuo Wang","doi":"10.1016/j.ejca.2024.115069","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Magnesium deficiency influences the activation and cytotoxicity of immune cells. Nevertheless, whether serum magnesium levels influence the clinical outcomes of immune checkpoint blockers (ICBs) treatment still remains ambiguous. There is an urgent need for clinical research to elucidate the relationship between serum magnesium levels and the outcomes of ICB therapy. Such insights could offer new perspectives on immunotherapy for cancer.</div></div><div><h3>Methods</h3><div>A multi-center retrospective study involving in pan-cancer patients treated with ICBs at three large cancer centers from August 2012 to May 2023 was conducted. The primary objective was to assess the correlation between serum magnesium levels and therapeutic response in patients receiving ICBs, and further evaluate the associations between serum magnesium levels and progression-free survival (PFS) and overall survival (OS).</div></div><div><h3>Results</h3><div>A total of 1441 patients treated with ICBs, including 1042 with lung cancer, 270 with esophageal cancer, and 129 with Hodgkin lymphoma, were enrolled in this study. We found that patients with elevated serum magnesium levels exhibited a favourable response to ICBs treatment. The optimal cut-off point for serum magnesium level (0.79 mmol/L) was applied for stratifying patients into distinct groups. In the three tumor cohorts, patients in high magnesium level group (Mg<sup>2+</sup> ≥ 0.79 mmol/L) had longer PFS and OS than those in low magnesium level group (Mg<sup>2+</sup> < 0.79 mmol/L). Univariate and multivariate analyses confirmed that the serum Mg<sup>2+</sup> level serves as an independent prognostic factor for cancer patients receiving ICBs therapy.</div></div><div><h3>Conclusion</h3><div>Our multi-center study demonstrated that among patients receiving ICBs therapy, those with elevated serum magnesium levels exhibit significantly better clinical outcomes than those with low serum magnesium levels. Further prospective validation studies are needed to confirm these findings.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":null,"pages":null},"PeriodicalIF":7.6000,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Elevated serum magnesium levels prompt favourable outcomes in cancer patients treated with immune checkpoint blockers\",\"authors\":\"Yingfang Feng , Meng Gao , Xiyue Xu , Hengqi Liu , Ke Lu , Zheng Song , Jingwei Yu , Xia Liu , Xue Han , Lanfang Li , Lihua Qiu , Zhengzi Qian , Shiyong Zhou , Huilai Zhang , Xianhuo Wang\",\"doi\":\"10.1016/j.ejca.2024.115069\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Magnesium deficiency influences the activation and cytotoxicity of immune cells. Nevertheless, whether serum magnesium levels influence the clinical outcomes of immune checkpoint blockers (ICBs) treatment still remains ambiguous. There is an urgent need for clinical research to elucidate the relationship between serum magnesium levels and the outcomes of ICB therapy. Such insights could offer new perspectives on immunotherapy for cancer.</div></div><div><h3>Methods</h3><div>A multi-center retrospective study involving in pan-cancer patients treated with ICBs at three large cancer centers from August 2012 to May 2023 was conducted. The primary objective was to assess the correlation between serum magnesium levels and therapeutic response in patients receiving ICBs, and further evaluate the associations between serum magnesium levels and progression-free survival (PFS) and overall survival (OS).</div></div><div><h3>Results</h3><div>A total of 1441 patients treated with ICBs, including 1042 with lung cancer, 270 with esophageal cancer, and 129 with Hodgkin lymphoma, were enrolled in this study. We found that patients with elevated serum magnesium levels exhibited a favourable response to ICBs treatment. The optimal cut-off point for serum magnesium level (0.79 mmol/L) was applied for stratifying patients into distinct groups. In the three tumor cohorts, patients in high magnesium level group (Mg<sup>2+</sup> ≥ 0.79 mmol/L) had longer PFS and OS than those in low magnesium level group (Mg<sup>2+</sup> < 0.79 mmol/L). Univariate and multivariate analyses confirmed that the serum Mg<sup>2+</sup> level serves as an independent prognostic factor for cancer patients receiving ICBs therapy.</div></div><div><h3>Conclusion</h3><div>Our multi-center study demonstrated that among patients receiving ICBs therapy, those with elevated serum magnesium levels exhibit significantly better clinical outcomes than those with low serum magnesium levels. Further prospective validation studies are needed to confirm these findings.</div></div>\",\"PeriodicalId\":11980,\"journal\":{\"name\":\"European Journal of Cancer\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":7.6000,\"publicationDate\":\"2024-10-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0959804924012000\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0959804924012000","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景镁缺乏会影响免疫细胞的活化和细胞毒性。然而，血清镁水平是否会影响免疫检查点阻断剂（ICBs）治疗的临床结果仍不明确。临床研究迫切需要阐明血清镁水平与 ICB 治疗结果之间的关系。这项多中心回顾性研究涉及 2012 年 8 月至 2023 年 5 月期间在三个大型癌症中心接受 ICBs 治疗的泛癌症患者。研究的主要目的是评估接受 ICBs 治疗的患者血清镁水平与治疗反应之间的相关性，并进一步评估血清镁水平与无进展生存期（PFS）和总生存期（OS）之间的关系。我们发现，血清镁水平升高的患者对 ICBs 治疗的反应良好。血清镁水平的最佳临界点（0.79 mmol/L）被用于将患者分为不同的组别。在三个肿瘤队列中，高镁水平组（Mg2+ ≥ 0.79 mmol/L）患者的PFS和OS均长于低镁水平组（Mg2+ < 0.79 mmol/L）患者。单变量和多变量分析证实，血清 Mg2+ 水平是接受 ICBs 治疗的癌症患者的一个独立预后因素。结论：我们的多中心研究表明，在接受 ICBs 治疗的患者中，血清镁水平升高者的临床预后明显优于血清镁水平低者。需要进一步的前瞻性验证研究来证实这些发现。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Elevated serum magnesium levels prompt favourable outcomes in cancer patients treated with immune checkpoint blockers

Background

Magnesium deficiency influences the activation and cytotoxicity of immune cells. Nevertheless, whether serum magnesium levels influence the clinical outcomes of immune checkpoint blockers (ICBs) treatment still remains ambiguous. There is an urgent need for clinical research to elucidate the relationship between serum magnesium levels and the outcomes of ICB therapy. Such insights could offer new perspectives on immunotherapy for cancer.

Methods

A multi-center retrospective study involving in pan-cancer patients treated with ICBs at three large cancer centers from August 2012 to May 2023 was conducted. The primary objective was to assess the correlation between serum magnesium levels and therapeutic response in patients receiving ICBs, and further evaluate the associations between serum magnesium levels and progression-free survival (PFS) and overall survival (OS).

Results

A total of 1441 patients treated with ICBs, including 1042 with lung cancer, 270 with esophageal cancer, and 129 with Hodgkin lymphoma, were enrolled in this study. We found that patients with elevated serum magnesium levels exhibited a favourable response to ICBs treatment. The optimal cut-off point for serum magnesium level (0.79 mmol/L) was applied for stratifying patients into distinct groups. In the three tumor cohorts, patients in high magnesium level group (Mg²⁺ ≥ 0.79 mmol/L) had longer PFS and OS than those in low magnesium level group (Mg²⁺ < 0.79 mmol/L). Univariate and multivariate analyses confirmed that the serum Mg²⁺ level serves as an independent prognostic factor for cancer patients receiving ICBs therapy.

Conclusion

Our multi-center study demonstrated that among patients receiving ICBs therapy, those with elevated serum magnesium levels exhibit significantly better clinical outcomes than those with low serum magnesium levels. Further prospective validation studies are needed to confirm these findings.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

European Journal of Cancer 医学-肿瘤学

CiteScore

11.50

自引率

4.80%

发文量

953

审稿时长

23 days

期刊介绍： The European Journal of Cancer (EJC) serves as a comprehensive platform integrating preclinical, digital, translational, and clinical research across the spectrum of cancer. From epidemiology, carcinogenesis, and biology to groundbreaking innovations in cancer treatment and patient care, the journal covers a wide array of topics. We publish original research, reviews, previews, editorial comments, and correspondence, fostering dialogue and advancement in the fight against cancer. Join us in our mission to drive progress and improve outcomes in cancer research and patient care.